Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0775
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports
Multidisciplinary
2019English

Cdk4/6-Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

Preclinical Evaluation of Exemestane as a Novel Chemotherapy for Gastric Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas

Laryngoscope
Otorhinolaryngology
2011English

P16 Methylation Increases the Sensitivity of Cancer Cells to the CDK4/6 Inhibitor Palbociclib

PLoS ONE
Multidisciplinary
2019English

Effects of Interleukin-3 on Myelosuppression Induced by Chemotherapy for Ovarian Cancer and Small Cell Undifferentiated Tumours

British Journal of Cancer
Cancer ResearchOncology
1993English

Preclinical Antitumor Activity of SST0116CL1: A Novel Heat Shock Protein 90 Inhibitor

International Journal of Oncology
Cancer ResearchOncology
2014English

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy